CCX832: Development discontinued

ChemoCentryx disclosed in an SEC filing that it and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) will discontinue development of CCX832 and its 2 backup compounds. ChemoCentryx said the decision was based on unblinded data from a Phase I trial in 40 healthy volunteers evaluating single doses of 1, 3, 10, 30 and 100 mg oral CCX832 and placebo. Details were not disclosed. ChemoCentryx said that it and GSK will continue "to have interest in further discussing possible strategic opportunities" for ChemR23. In 2006, the company granted GSK an option to develop and commercialize ChemoCentryx's programs targeting chemokine and chemoattractant receptors, including CCX832 (see BioCentury, Aug. 28, 2006). ...